Tuesday, November 24, 2009, 5:01AM AEST - The Australian Stockmarket opens in 4 hours and 59 minutes.
To create a watchlist or portfolio of shares, Register

Neurogen Corp. (NRGN)

3:24AM AEST: 0.179 USD  Up 0.009 (5.29%)  
 MORE ON NRGN 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Neurogen Corporation (NGM:NRGN) Delayed quote dataEdit
Last Trade:0.179 USD
Trade Time: 3:24AM AEST
Change:Up 0.009 (5.29%)
Prev Close:0.17
Open:0.17
Bid:0.173 x 500
Ask:0.179 x 400
1y Target Est:3.00
Day's Range:0.17 - 0.17
52wk Range:0.06 - 2.07
Volume:37,500
Avg Vol (3m):569,247
Market Cap:12.36M
P/E (ttm):N/A
EPS (ttm):-0.366
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add NRGN to Portfolio   Download Data

 HEADLINES 
NEUROGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Thu, Nov 19)
NEUROGEN CORP Financials
EDGAR Online Financials (Sat, Nov 14)
New Star Analyst Rankings for Neurogen Corporation
StarMine (Wed, Nov 11)
NEUROGEN CORP Files SEC form 10-Q/A, Quarterly Report
EDGAR Online (Tue, Nov 10)
Neurogen Corporation Earnings Call scheduled for 8:30 am ET today
CCBN (Sat, Nov 7)
NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Con
EDGAR Online (Fri, Nov 6)
Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
Business Wire (Fri, Nov 6)
Neurogen Corporation Announces Webcast of Third Quarter 2009 Financial Results on November 6
Business Wire (Thu, Nov 5)
NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
EDGAR Online (Tue, Aug 25)
Neurogen Corporation Earnings Call scheduled for 5:00 pm ET today
CCBN (Sat, Aug 15)
More Headlines for NRGN...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.38
EPS Est (in 2 years) (Dec-10) :-0.27
Avg Rec (current)*:5.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Neurogen Corporation engages in the development of new small molecule drugs for psychiatric and neurological disorders. The company’s clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of P...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices